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Background:  The Dose Adjustment For Normal Eating (DAFNE) trial was a waiting-list-
controlled study of 5 days’ training in flexible, intensive insulin therapy in a group of 135 
adults with Type 1 diabetes in the UK. At 6 months (m), DAFNE improved glycaemic control 
without increasing severe hypoglycaemia, while significantly reducing the negative impact 
of diabetes on quality of life (QoL) and improving other patient reported outcomes (PROs).   
Aim:  To evaluate long-term efficacy of DAFNE training.  Methods:  At 44m follow-up 
(range: 37-51m), 108 (80%) trial participants provided biomedical data and 88 (65%) 
completed questionnaires, including ADDQoL (measuring impact of diabetes on QoL).  
Results:  At 44m, HbA1c (8.96±1.2%) had deteriorated from 12m (8.75±1.2%, p<0.05) but 
remained improved from baseline (9.32±1.1%, p<0.01). All QoL outcomes remained 
significantly improved from baseline with no difference between 12m and 44m (e.g. impact 
of diabetes on dietary freedom: -1.78±2.33 at 44m vs -4.27±2.94 at baseline, p<0.0001; vs 
1.80±2.32 at 12m, ns).  Conclusions:  The impact of a single DAFNE course on glycaemic 
control is reduced but still apparent in the long term. Additional input may be needed to 
maintain the initial response.  In contrast, improvements in QoL and other PROs were well 
maintained over approximately 4 years.  
 
 
